Alaunos Therapeutics (TCRT) Operating Leases (2020 - 2021)

Alaunos Therapeutics' (TCRT) quarterly Operating Leases came in at $4.7 million in Q3 2021, down 3.74% on a QoQ basis from $4.9 million in Q2 2021.

Alaunos Therapeutics (TCRT) Operating Leases (2020 - 2021) Analysis & Trends

Alaunos Therapeutics (TCRT) has 2 years of Operating Leases data on file, last reported at $4.7 million in Q3 2021.

Quarterly Operating Leases changed N/A year-over-year to $4.7 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $4.7 million (changed N/A YoY) and the FY2020 annual result came in at $4.0 million, changed N/A from the prior year.
Operating Leases eased to $4.7 million in Q3 2021, from $4.9 million in the prior quarter.
In the past five years, Operating Leases ranged from a high of $4.9 million in Q2 2021 to a low of $4.0 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Alaunos Therapeutics	4.28 Mn	4.16 Mn	-

Download Data